Valuation: Alterity Therapeutics Limited

Market Cap 82.98M 71.91M 67.32M 61.43M 116M 7.91B 118M 789M 309M 3.96B 312M 305M 13.22B P/E 2026 *
-0.41x
P/E 2027 * -0.42x
Enterprise Value 37.79M 32.75M 30.66M 27.98M 52.65M 3.6B 53.53M 360M 141M 1.8B 142M 139M 6.02B EV / Sales 2026 *
11.5x
EV / Sales 2027 * 16.8x
Free-Float
91.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alterity Therapeutics Limited

1 day+0.93%
1 week-8.47%
Current month-0.92%
1 month-14.96%
3 months-1.82%
6 months+35.00%
Current year+35.00%
1 week 0.51
Extreme 0.51
0.57
1 month 0.5
Extreme 0.495
0.64
Current year 0.35
Extreme 0.35
0.78
1 year 0.35
Extreme 0.35
0.78
3 years 0.1
Extreme 0.1
0.95
5 years 0.1
Extreme 0.1
1.7
10 years 0.1
Extreme 0.1
20.5
Manager TitleAgeSince
Chief Executive Officer 65 07/01/2021
Director of Finance/CFO - 30/09/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 70 29/07/2005
Director/Board Member 47 08/08/2011
Director/Board Member 65 21/11/2025
Date Insider Type Main position Quantity % Market Cap.
6/15/26 A Free

Director

1,000,000 0.0092%
1/7/26 A Expiration

Chief Executive Officer

91,392,720 0.8404%
9/17/25 A Expiration

Director

7,000,000 0.1052%
Change 5-day change 1-year change 3-year change Capi.($)
+0.93%-8.47%-28.00%+54.29% 82.21M
-0.72%+3.41%+6.32%+16.27% 50.03B
-0.40%+6.36%+493.00%+586.13% 44.36B
+0.67%+11.92%+24.77%+82.88% 40.82B
+0.98%+7.18%+35.82%+11.26% 39.83B
+4.73%+15.53%+26.95%+54.62% 32.51B
-0.87%+3.71% - - 16.85B
+0.63%+5.23%+34.55%+126.75% 16.81B
-0.20%+1.57%+5.49%+21.35% 14.05B
+1.25%+19.20%+87.39%+30.13% 13.22B
Average +0.74%+252.02%+76.25%+109.30% 26.86B
Weighted average by Cap. +0.69%+295.23%+108.50%+140.06%

Financials

2026 *2027 *
Net sales 3.29M 2.85M 2.67M 2.44M 4.58M 314M 4.66M 31.3M 12.26M 157M 12.35M 12.08M 524M 2.5M 2.17M 2.03M 1.85M 3.49M 239M 3.55M 23.82M 9.33M 120M 9.4M 9.2M 399M
Net income -14.64M -12.69M -11.88M -10.84M -20.4M -1.4B -20.74M -139M -54.58M -699M -54.98M -53.78M -2.33B -29.66M -25.7M -24.06M -21.96M -41.32M -2.83B -42.01M -282M -111M -1.42B -111M -109M -4.72B
Net Debt -45.19M -39.16M -36.66M -33.45M -62.95M -4.31B -64M -430M -168M -2.16B -170M -166M -7.2B -40.88M -35.43M -33.17M -30.26M -56.95M -3.9B -57.9M -389M -152M -1.95B -153M -150M -6.51B
Logo Alterity Therapeutics Limited
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Employees
9
Date Price Change Volume
11/08/26 A$0.5400 +0.93% 13,665
10/08/26 A$0.5350 +3.88% 47,330
07/08/26 A$0.5150 -1.90% 65,719
06/08/26 A$0.5250 -5.41% 218,904
05/08/26 A$0.5550 -0.89% 32,640
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.5400AUD
Average target price
2.280AUD
Spread / Average Target
+322.22%

Quarterly revenue - Rate of surprise